BMY

The Week

Bristol Myers Squibb (BMY) closed at $62.86, down 0.32% from the prior Friday. The S&P 500 rose 1.21% over the same stretch, leaving BMY about 1.53 percentage points behind the benchmark. The week tracked lower through Thursday before Friday’s rebound. The stock slipped from $62.62 on Monday to $61.15 by Wednesday, touched a session low of $60.595 on Thursday, then recovered to finish at $62.86 on Friday. It was a week of drift lower followed by a sharp end-of-week bounce.

Key Events

Sichuan Biokin Pharmaceutical’s unit received a milestone payment from Bristol Myers Squibb on Monday, confirming the collaboration remains on track. On Friday the company disclosed two items: FDA accelerated approval for ZENBEXUS as a combination therapy in multiple myeloma, and Phase 3 EXCALIBER-RRMM data showing a 41.1% MRD-negative complete response rate. The same day Flynn reiterated a sell rating with a $40 target, citing pipeline uncertainty and limited upside for the IPF asset. BMS also joined RAAP midweek and helped raise over $3.6 million at the One Mind Music Festival.

Analyst Ratings

Across 29 institutions covering the stock, 7 rate it buy, 3 rate it overweight, 17 rate it hold, and 1 rates it sell; none rate it underweight, and 1 has no opinion. The consensus rating is buy, with a consensus target of $66.71, about 6.12% above the current price. Targets range from $40 to $82, a wide spread that points to genuine disagreement on valuation. The stock ranks 2nd among 203 pharmaceutical names in analyst rating. On valuation, it trades at 13.83x earnings, 5.75x book, and yields about 3.99%.

The Week Ahead

Tuesday brings a cluster of macro data: FHFA house prices, Case Shiller home price indices, JOLTS job openings, and consumer confidence, all feeding into the rates debate. Monday has the Dallas Fed manufacturing activity index. Company-specific focus lands on the fiscal Q3 earnings release scheduled for 29 October before the open, with consensus at $1.46 EPS and $12.7 billion in revenue. Meanwhile, the commercial rollout of ZENBEXUS and further readouts from EXCALIBER-RRMM will stay on the radar.

In Short

The tape this week was soft relative to the market, but the rating backdrop skews constructive: consensus rating is buy with the target above spot, even as the $40 to $82 target range shows how divided analysts are on fair value. The latest session’s flow shows small-lot money as a clear net buyer, while large and medium lots were closer to balanced, so the flow picture does not lean strongly either way. Friday’s bounce erased most of the weekly loss. What matters next is whether the ZENBEXUS launch and the Q3 print give current valuations something to build on; for now the stock sits between a supportive rating skew and a still-cautious tape.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.